Helgi van de Velde

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

Jesús F. San Miguel, Rudolf Schlag, Nuriet K. Khuageva et al. · New England Journal of Medicine · 2008 · 1.9K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.

B Coiffier, E.A. Osmanov, Xin Hong et al. · The Lancet Oncology · 2011 · 1.6K citations

Medicine, Hematology, Pharmacotherapy +13

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Philippe Moreau, Tamás Masszi, Norbert Grząśko et al. · New England Journal of Medicine · 2016 · 1.1K citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki et al. · The Lancet Oncology · 2011 · 917 citations

Medicine, Pharmacology, Pharmacotherapy +15

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

Pieter Sonneveld, Ingo Schmidt‐Wolf, Bronno van der Holt et al. · Journal of Clinical Oncology · 2012 · 826 citations · Full text

Medicine, Hematology, Pharmacotherapy +16